Recently, Shanghai RAAS's product Human Thrombin (commonly known as human thrombin) has been approved and issued the "Drug Supplementary Application Approval Notice" for human thrombin by the National Medical Products Administration.

At present, there are five clinical classifications of hemostatic drugs, namely hemostatic drugs that act on the blood vessel wall, hemostatic drugs that act on platelets, hemostatic drugs that act on coagulation mechanisms, drugs that promote coagulation factor synthesis, and topical hemostatic therapy drugs. Shanghai RAAS human thrombin belongs to the category of topical hemostatic therapy drugs. It is a local hemostatic drug that is used to assist in the treatment of bleeding in general surgical abdominal incisions, liver surgical wounds, and tonsil surgical wounds.

The approval this time is of great significance. It not only means the improvement of the comprehensive utilization rate of Shanghai RAAS raw material plasma, but also means that Shanghai RAAS has achieved a new leap in pursuing quality management and lean management development as always. In the future, Shanghai RAAS will further increase investment, accelerate the pace of listing human thrombin and research and development of new products.